Default: Journal of Acquired Immune Deficiency Syndromes

ISSN: 1525-4135

Journal Home

Journal Guideline

Journal of Acquired Immune Deficiency Syndromes Q1 Unclaimed

Lippincott Williams and Wilkins Ltd. United States
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Acquired Immune Deficiency Syndromes is a journal indexed in SJR in Infectious Diseases and Pharmacology (medical) with an H index of 152. It has an SJR impact factor of 2,165 and it has a best quartile of Q1.

Journal of Acquired Immune Deficiency Syndromes focuses its scope in these topics and keywords: hiv, health, viral, infant, expression, women, antiretroviral, therapy, cd, public, ...

Type: Journal

Type of Copyright:


Open Access Policy:

Type of publications:

Publication frecuency: -


- €

Gold OA


Green OA

0 €

Non OA


Journal of Acquired Immune Deficiency Syndromes


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)



Aims and Scope

hiv, health, viral, infant, expression, women, antiretroviral, therapy, cd, public, voluntary, care, acid, prevention, load, risk, united, trial, testing, cell, circumcision, diagnosis, men, rakai, randomized, suppression, t, youth,

Best articles

129 Human Endogenous Retrovirus-K (HML-2) Elements in the Plasma of People with Lymphoma and Breast Cancer

View more

A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients

View more

A Prognostic Model for HIV Seroconversion Among Injection Drug Users as a Tool for Stratification in Clinical Trials

View more

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

View more

A Study Comparing Sexually Transmitted Infections and HIV Among Ex-Red-Light District and Non-Red-Light District Sex Workers After the Demolition of Baina Red-Light District

View more

Addition of Single-Dose Tenofovir and Emtricitabine to Intrapartum Nevirapine to Reduce Perinatal HIV Transmission

View more

Addressing Poor Retention of Infants Exposed to HIV

View more

Adequacy of Prenatal Care and Prescription of Zidovudine to Prevent Perinatal HIV Transmission

View more

An Exploratory Study of Correlates of Allostatic Load in Older People Living With HIV

View more

An Intervention to Support HIV Preexposure Prophylaxis Adherence in HIV-Serodiscordant Couples in Uganda

View more

Antibodies From HIV-Positive and AIDS Patients Bind to an HIV Envelope Multivalent Vaccine

View more

Bacterial and Mycobacterial Meningitis in HIV-Positive Compared with HIV-Negative Patients in an Internal Medicine Ward in Libreville, Gabon

View more

Bone Mineral Density Declines Twice as Quickly Among HIV-Infected Women Compared With Men

View more

Brief Report

View more

Brief Report

View more

C-Reactive Protein Is an Independent Predictor of Mortality in Women With HIV-1 Infection

View more

Can HIV-Infected Patients Fast During the Month of Ramadan?

View more

Cerebrospinal Fluid HIV RNA and Drug Levels With Combination Ritonavir and Saquinavir

View more

Changes in Cognition During Antiretroviral Therapy: Comparison of 2 Different Ranking Systems to Measure Antiretroviral Drug Efficacy on HIV-Associated Neurocognitive Disorders

View more

Chemotherapy Consisting of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine With Granulocyte-Colony-Stimulating Factor in HIV-Infected Patients With Newly Diagnosed Hodgkin's Disease: A Prospective, Multi-institutional AIDS Clinical Trials Group

View more


View more

Clinical Impact of HTLV-1 Infection in Spain: Implications for Public Health and Mandatory Screening

View more

Clinical Utility of Resistance Testing: Retrospective and Prospective Data Supporting Use and Current Recommendations

View more

Comparison of Generic Zidovudine + Lamivudine (Cipla, Duovir) and the GlaxoSmithKline Brand (Combivir) Tablets

View more


No comments ... Be the first to comment!